DURHAM, N.C., March 1, 2016 /PRNewswire/ -- Novan, Inc. today announced that data from a Phase 2 clinical trial to evaluate the efficacy and safety of the Company’s topical nitric oxide product candidate SB204 Gel for the treatment of acne vulgaris will be presented at the 74th Annual Meeting of the American Academy of Dermatology (“AAD”) in Washington, D.C.
Lawrence Eichenfield, MD, is scheduled to present “Efficacy and Safety of SB204 Gel in the Treatment of Acne Vulgaris” on Saturday, March 5, during a Late-breaking Research in Dermatology Forum. Dr. Eichenfield is Chief of Pediatric and Adolescent Dermatology at San Diego Rady Children’s Hospital and Professor of Dermatology and Pediatrics at the University of California, San Diego School of Medicine.
Top-line results from Novan’s Phase 2b trial with SB204 for the treatment of acne were originally announced in September 2015. Novan announced earlier this month that the first patient has been dosed in the Company’s Phase 3 program with SB204.
About the Presentation
Abstract Number: 3792
Title: “Efficacy and Safety of SB204 Gel in the Treatment of Acne Vulgaris”
Authors: L. Eichenfield, L. Stein-Gold, J. Quiring, C. Enloe, M.J. Rico
Presenter: Lawrence Eichenfield, MD
Date and Time: Saturday, March 5, 2016, 11:48 a.m. ET
Session: F053, Late-Breaking Research Clinical Trials
About Acne
According to AAD, acne is a chronic inflammatory skin condition, characterized by comedones (blackheads and whiteheads), pimples and deeper lumps (cysts or nodules) that occur on the face, neck, chest, back, shoulders and upper arms. It is the most common skin condition in the United States, affecting up to 50 million Americans annually. Approximately 85% of people between the ages of 12 and 24 experience at least minor acne.1
About Novan
Novan, Inc. is a late-stage pharmaceutical company focused on redefining the standard of care in dermatology through the development and commercialization of innovative therapies using the Company’s nitric oxide platform. Nitric oxide plays a vital role in the natural immune system response against microbial pathogens and is a critical regulator of inflammation. Our ability to harness nitric oxide and its multiple mechanisms of action has enabled us to create a pipeline of differentiated, first-in-class product candidates. We are rapidly advancing a pipeline in five dermatological indications with significant unmet medical need. We believe that our platform allows us the potential to significantly improve patient outcomes and positions us to be a commercially successful leader in the dermatology market.
For more information, visit the Company’s website at www.novantherapeutics.com.
Forward-Looking Statements
This press release contains forward-looking statements including, but not limited to, statements related to pharmaceutical development of nitric oxide-based product candidates and future prospects. Forward-looking statements are subject to a number of risks and uncertainties that could cause actual results to differ materially from our expectations. These forward-looking statements speak only as of the date of this press release, and Novan disclaims any intent or obligation to update these forward-looking statements, except as expressly required by law.
References
1 American Academy of Dermatology. “Acne.” https://www.aad.org/media/stats/conditions (Feb. 26, 2016).
CONTACT:
(Investors)
Sean Andrews, Senior Director of Investor Relations
Novan, Inc.
919-908-2420
sandrews@novantherapeutics.com
(Media)
Deb Holliday
Pascale Communications, LLC
412-877-4519
deb@pascalecommunications.com
Logo - http://photos.prnewswire.com/prnh/20160222/336123LOGO
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/novans-phase-2b-results-with-sb204-to-be-presented-at-aad-300228575.html
SOURCE Novan, Inc.
